Neurohumoral mechanisms involved in congestive heart failure.

[1]  J. Cohn,et al.  Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.

[2]  L. I. Goldberg,et al.  A comparison of the vascular dopamine receptor with other dopamine receptors. , 1978, Annual review of pharmacology and toxicology.

[3]  A. A. Taylor,et al.  Propylbutyldopamine: Hemodynamic Effects in Conscious Dogs, Normal Human Volunteers and Patients with Heart Failure , 1983, Circulation.

[4]  W. Feldberg,et al.  The action of peptides on the adrenal medulla. Release of adrenaline by bradykinin and angiotensin , 1964, The Journal of physiology.

[5]  J. Cohn,et al.  The Neurohumoral and Hemodynamic Response to Orthostatic Tilt in Patients with Congestive Heart Failure , 1983, Circulation.

[6]  F. Abboud,et al.  Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin. , 1980, The American journal of physiology.

[7]  Cowley Aw,et al.  Role of vasopressin in cardiovascular regulation. , 1983 .

[8]  R. Nadeau,et al.  Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. , 1977, Circulation research.

[9]  M. Manning,et al.  Design and uses of selective agonistic and antagonistic analogs of the neuropeptides oxytocin and vasopressin , 1984, Trends in Neurosciences.

[10]  S. Z. Langer,et al.  Recent developments in vascular smooth muscle pharmacology: the post-synaptic α2-adrenoceptor , 1982 .

[11]  J. Federman,et al.  Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.

[12]  J. Laragh,et al.  Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients. , 1976, The American journal of medicine.

[13]  D. Jacobowitz,et al.  Increased dopamine in the failing hamster heart: transvesicular transport of dopamine limits the rate of norepinephrine synthesis. , 1982, The American journal of cardiology.

[14]  R. Gorlin,et al.  Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure , 1979, Circulation.

[15]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[16]  S. Z. Langer.  Presynaptic regulation of the release of catecholamines. , 1980, Pharmacological reviews.

[17]  A. Sjoerdsma,et al.  ELUCIDATION OF THE RATE-LIMITING STEP IN NOREPINEPHRINE BIOSYNTHESIS IN THE PERFUSED GUINEA-PIG HEART. , 1965, The Journal of pharmacology and experimental therapeutics.

[18]  G. Ross.  Adrenergic responses of the coronary vessels. , 1976, Circulation research.

[19]  Y. Yamane.  Plasma ADH level in patients with chronic congestive heart failure. , 1968, Japanese circulation journal.

[20]  L. Share.  Interrelations between vasopressin and the renin-angiotensin system. , 1979, Federation proceedings.

[21]  J. Cohn,et al.  The effects of bromocriptine in patients with congestive heart failure. , 1983, American heart journal.

[22]  D. Harrison,et al.  Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. , 1983, American heart journal.

[23]  R. Roth,et al.  Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation , 1971, British journal of pharmacology.

[24]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.

[25]  D. Goldstein,et al.  Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. , 1981, The American journal of cardiology.

[26]  K. Malik.  Prostaglandins--modulation of adrenergic nervous system. , 1978, Federation proceedings.

[27]  P. A. Zwieten,et al.  Cardiovascular α2-receptors , 1983 .

[28]  R. Moulds,et al.  Facilitatory prejunctional β-adrenoceptors in human arteries and veins , 1983 .

[29]  L. Toll,et al.  Role of Mg2+-ATPase and a pH gradient in the storage of catecholamines in synaptic vesicles. , 1978, Biochemistry.

[30]  S. Udenfriend,et al.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.

[31]  R. Roth,et al.  Angiotensin accelerates Catecholamine Biosynthesis in Sympathetically Innervated Tissues , 1969, Nature.

[32]  T. Nicholas.  Potentiation of the effects of noradrenaline and of sympathetic stimulation of the perfused rat caudal artery by angiotensin , 1970, The Journal of pharmacy and pharmacology.

[33]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[34]  J. Laragh.  Hormones and the Pathogenesis of Congestive Heart Failure: Vasopressin, Aldosterone, and Angiotensin II Further Evidence for Renal‐Adrenal Interaction from Studies in Hypertension and in Cirrhosis , 1962, Circulation.

[35]  R. Arbogast,et al.  Greatly Enhanced Pressor Response to Antidiuretic Hormone in Patients with Impaired Cardiovascular Reflexes Due to Idiopathic Orthostatic Hypotension , 1980, Journal of cardiovascular pharmacology.

[36]  M. Sole,et al.  Effects of bromocriptine on plasma catecholamines in normal men. , 1979, Neuroendocrinology.

[37]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[38]  P. Khairallah,et al.  Inhibition of noradrenaline uptake by angiotensin , 1967, The Journal of pharmacy and pharmacology.

[39]  Zimmerman Bg.  Actions of angiotensin on adrenergic nerve endings. , 1978 .

[40]  S. Z. Langer.  SIXTH GADDUM MEMORIAL LECTURE NATIONAL INSTITUTE FOR MEDICAL RESEARCH, MILL HILL, JANUARY 1977 , 1977, British journal of pharmacology.

[41]  S. Z. Langer,et al.  POSSIBLE ROLE OF A β‐ADRENOCEPTOR IN THE REGULATION OF NORADRENALINE RELEASE BY NERVE STIMULATION THROUGH A POSITIVE FEED‐BACK MECHANISM , 1975, British journal of pharmacology.

[42]  S. Oparil,et al.  Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. , 1984, The Journal of pharmacology and experimental therapeutics.

[43]  T. Slotkin,et al.  SYNAPTIC VESICLES ISOLATED FROM RAT HEART: l‐[3H]NOREPINEPHRINE UPTAKE PROPERTIES 1 , 1979, Journal of neurochemistry.

[44]  R McCarty,et al.  Relationship between plasma norepinephrine and sympathetic neural activity. , 1983, Hypertension.

[45]  G. Ross,et al.  Effects of a cardio-selective beta-adrenergic blocking agent on the heart and coronary circulation. , 1970, Cardiovascular research.

[46]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[47]  S. Langer,et al.  PRESYNAPTIC RECEPTORS AND THEIR ROLE IN THE REGULATION OF TRANSMITTER RELEASE. , 1977 .

[48]  M. Fregly,et al.  Effect of in vitro administration of captopril on vascular reactivity of rat aorta. , 1982, Hypertension.

[49]  J. Montani,et al.  Hemodynamic Effects of Exogenous and Endogenous Vasopressin at Low Plasma Concentrations in Conscious Dogs , 1980, Circulation research.

[50]  D L Eckberg,et al.  Defective cardiac parasympathetic control in patients with heart disease. , 1971, The New England journal of medicine.

[51]  H. Sarau,et al.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. , 1982, The Journal of pharmacology and experimental therapeutics.

[52]  J. T. Shepherd,et al.  Metabolic modulation of neurotransmitter release--adenosine, adenine nucleotides, potassium, hyperosmolarity, and hydrogen ion. , 1978, Federation proceedings.

[53]  J. Shiloach,et al.  The evolutionary origins of hormones, neurotransmitters, and other extracellular chemical messengers: implications for mammalian biology. , 1982, The New England journal of medicine.

[54]  M. Sole,et al.  A possible change in the rate-limiting step for cardiac norepinephrine synthesis in the cardiomyopathic Syrian hamster. , 1977, Circulation research.

[55]  I. Shoulson,et al.  Bromocriptine inhibits norepinephrine release , 1979, Clinical pharmacology and therapeutics.

[56]  M. Karmazyn,et al.  Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. , 1978, Endocrinology.

[57]  E. Sharpey-Schafer,et al.  Effects of Valsalva's Manœuvre on the Normal and Failing Circulation , 1955, British medical journal.

[58]  L. I. Goldberg,et al.  Peripheral dopamine receptors: A classification based on potency series and specific antagonism , 1983 .

[59]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[60]  J. Cohn,et al.  Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.